Drug intelligence / Profile preview

PANAF-Premium

Development stage
Unknown
Lead developer
Premium Serums and Vaccines
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**PANAF-Premium** is a polyvalent, enzyme-refined equine snake antivenom for treatment of clinically significant snakebite envenoming in sub-Saharan Africa. It contains purified equine immunoglobulin F(ab′)2 fragments raised against African snake venoms and is supplied as a lyophilized antiserum with sterile water for injection. The product is administered intravenously after reconstitution and neutralizes circulating venom toxins from medically important African *Bitis*, *Echis*, *Naja*, and *Dendroaspis* species. It is manufactured by Premium Serums & Vaccines and has received a WHO risk-benefit recommendation for specified sub-Saharan African snake species; a Phase IV study in northern Cameroon evaluated post-marketing safety and effectiveness. ([extranet.who.int](https://extranet.who.int/prequal/sites/default/files/document_files/PANAF-Premium%20single%20vial%2001032023.pdf))

Brand names
PANAF-Premium
Other names
Snake Venom Antiserum Pan Africa

Beyond the preview

Go deeper on PANAF-Premium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PANAF-Premium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call